大湾区资讯 - 港澳药械通
There was an update on 7 Jul 2022 from GDMPA about the 3rd phases drugs and MD. There are 8 MDs being listed for HKUSZ Hospital and SZ C-Mer Dennis Lam Eye Hospital and 4 medicines being approved. And there is one medicine had been delisted due to the drug was launched in China market by end of Apr.
The measures have been implemented for one year (27 Aug was the anniversary), GDMPA has approved 20 medicines and 12 MDs which benefited to 500 patients. They will further increase the categories and extend to more hospitals and organizations gradually. The application for listing a product is 10 working days for medicines and 15 working days for MD. The repeat application is 1 work day. In addition, the GDMPA will setup an urgent clinical use drugs and MD database to facilitate and shorten the application time. Besides, the development of GBA Real World Evidence Policy Study will also help to enhance the development of this measures. The GBA will be a good platform to study the other global real world evidence data, insurance budgeting and policy application for supporting the MD listed in China.